Wolfgang Miesbach on Transforming Care for Women and Girls with Bleeding Disorders: Key Guidelines 2021–2024
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Advancing Care for Women and Girls with Bleeding Disorders
The clinical landscape has transformed significantly through evidence-based guidelines (2021-2024), finally addressing historical gaps in care for this mainly unrecognized population:
2021 ISTH Nomenclature Revolution
Eliminated outdated ‘carrier’ terminology
Established 5 evidence-based categories from severe to asymptomatic women and girls with bleeding disorders
Improved diagnostic accuracy and research uniformity
2021 ASH/ISTH/NHF/WFH VWD Guidelines
Prioritized hormonal therapy and tranexamic acid over desmopressin for heavy menstrual bleeding
Set clear diagnostic thresholds: <0.30 IU/mL (regardless of bleeding) and <0.50 IU/mL (with bleeding)
2021 European Principles of Care
EAHAD and EHC established 10 comprehensive care principles
Promoted systematic screening across European centers
2024 NBDF MASAC Guidelines
Document 286: Most comprehensive update yet
Mandated iron deficiency screening even with normal hemoglobin
Addressed historical underdiagnosis gaps
Persistent Challenges:
Despite progress, women and girls with bleeding disorders remain systematically excluded from clinical trials, creating dangerous knowledge gaps that impact:
Diagnostic delays
Higher anemia & transfusion rates
Unnecessary hysterectomies
25% report severe reproductive decision impact
The path forward requires collaborative research and gender-specific treatment studies to truly close these healthcare disparities.”
Stay informed with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis